Kliniken & Institute ... Kliniken Chirurgische Klinik... Allgemein-, Viszeral-... Forschung Pankreasforschung Sektion... AG Molekulare... Publikationen Ausgewählte...

10 ausgewählte Publikationen aus 114 peer-review Manuskripten

  1. Friesen C*, Herr I* (*equal contribution), Krammer P and Debatin K-M (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis of leukemia cells. Nature Med 2, 574 - 577. IF2016 29.886
  2. Herr I, Wilhelm D, Boehler T, Angel P and Debatin K-M (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J 16, 6200-6208. IF2016 9.792
  3. Herr I, Krilleke, D and Debatin K-M. (2000). A sensitive, non-radioactive and fast method for detection of JNK/SAPK activity in leukemic T cells, Leukemia 14, 1859-1860. IF2016 11.702
  4. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer, PH, Knebel-Döberitz M and Debatin K-M (2003). Glucocorticoid co-treatment induces apoptosis resistance towards cancer therapy in carcinomas. Cancer Res 63, 3112-3120. IF2016 9.112
  5. Wenger T, Mattern J, Penzel R, Gassler N, Haas T, Sprick M, Walczak H, Krammer PH, Debatin K-M and Herr I (2006). Specific resistance uponlentiviral TRAIL transfer by intracellular retention of TRAIL receptors. Cell Death Differ 13, 1740-1751. IF2016 8.339
  6. Herr I and Pfitzenmaier J (2006). Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7, 425-426. IF2016 33.900
  7. Herr I, Schemmer P and Büchler MW. (2007). On the TRAIL to therapeutic intervention in liver disease. Hepatology 46, 266-274. IF2016 13.246
  8. Kallifatidis G, Rausch V, Baumann B, Apel A, Beckermann BM, Groth A, Mattern J, Li Z, Kolb A, Moldenhauer G, Altevogt P, Wirth T, Werner J, Schemmer P, Büchler MW, Salnikov AV and Herr I (2009). Sulforaphane targets panceatic tumor-initiating cells by NF-kB-induced anti-apoptotic signaling. GUT 58, 949-963. IF2016 16.658
  9. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, Salnikov A and Herr I. (2010). Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell charcteristics. Cancer Res 70, 5004-5013. IF2016 9.112
  10. Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E,  Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G and Herr I. (2012). New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody for tumor targeting. Clin Cancer Res 18, 1028-1038. IF2016 9.619